

# Permixon (R) 320 mg once a day open label treatment for patients participating in the placebo controlled study

|                                        |                                                              |                                                      |
|----------------------------------------|--------------------------------------------------------------|------------------------------------------------------|
| <b>Submission date</b><br>12/09/2003   | <b>Recruitment status</b><br>No longer recruiting            | <input type="checkbox"/> Prospectively registered    |
| <b>Registration date</b><br>12/09/2003 | <b>Overall study status</b><br>Completed                     | <input type="checkbox"/> Protocol                    |
| <b>Last Edited</b><br>12/10/2016       | <b>Condition category</b><br>Urological and Genital Diseases | <input type="checkbox"/> Statistical analysis plan   |
|                                        |                                                              | <input type="checkbox"/> Results                     |
|                                        |                                                              | <input type="checkbox"/> Individual participant data |
|                                        |                                                              | <input type="checkbox"/> Record updated in last year |

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr T Terry

**Contact details**  
University Hospitals of Leicester  
c/o Research and Development Office  
Leicester General Hospital NHS Trust  
Leicester  
United Kingdom  
LE1 4PW  
+44 (0)116 258 4109  
research@lri.org.uk

## Additional identifiers

**Protocol serial number**  
N0123112704

## Study information

**Scientific Title**

Permixon (R) 320 mg once a day open label treatment for patients participating in the placebo controlled study

**Study objectives**

Not provided at time of registration

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Primary study design**

Interventional

**Study design**

Randomised controlled trial

**Study type(s)**

Not Specified

**Health condition(s) or problem(s) studied**

Benign prostatic hyperplasia (BPH)

**Interventions**

Permixon (R) 320 mg once a day versus placebo

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

Not provided at time of registration

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

19/02/2004

**Eligibility****Key inclusion criteria**

Not available.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

20/02/2000

**Date of final enrolment**

19/02/2004

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

University Hospitals of Leicester

Leicester

United Kingdom

LE1 4PW

**Sponsor information****Organisation**

Department of Health (UK)

**Funder(s)****Funder type**

Government

**Funder Name**

# Results and Publications

## Individual participant data (IPD) sharing plan

**IPD sharing plan summary**  
Not provided at time of registration

### Study outputs

| Output type                   | Details       | Date created | Date added | Peer reviewed? | Patient-facing? |
|-------------------------------|---------------|--------------|------------|----------------|-----------------|
| <a href="#">Study website</a> | Study website | 11/11/2025   | 11/11/2025 | No             | Yes             |